Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.7%

18 terminated/withdrawn out of 87 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

6%

5 trials in Phase 3/4

Results Transparency

0%

0 of 30 completed trials have results

Key Signals

16 recruiting16 terminated

Enrollment Performance

Analytics

Phase 2
38(59.4%)
N/A
17(26.6%)
Phase 3
4(6.3%)
Phase 1
4(6.3%)
Phase 4
1(1.6%)
64Total
Phase 2(38)
N/A(17)
Phase 3(4)
Phase 1(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (87)

Showing 20 of 87 trials
NCT06713837Phase 3Recruiting

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Role: lead

NCT06459024Recruiting

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Role: lead

NCT07372261Enrolling By Invitation

Validation of a Prognostic Method for Assessing the Risk of Distant Metastasis in Early-stage Breast Cancer

Role: collaborator

NCT03269227Not ApplicableActive Not Recruiting

Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma

Role: lead

NCT06909968Completed

Identification of Palliative Care Needs and Prognostic Factors of Survival in Tailoring Appropriate Interventions in Advanced Oncological, Renal and Pulmonary Diseases

Role: lead

NCT05867615Phase 2Active Not Recruiting

Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:

Role: lead

NCT04826458Not ApplicableCompleted

Clinical Study Comparing Different Strategies to Increase Adherence to Oral Therapies in Oncohematology

Role: lead

NCT03898128Completed

ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjugate

Role: lead

NCT05893381Phase 2Recruiting

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)

Role: lead

NCT07137221Completed

Acupuncture And Inflammatory Status In Breast Cancer Patients With Climateric Syndrome.

Role: lead

NCT04523688Phase 2Recruiting

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma

Role: lead

NCT05623319Phase 2Recruiting

Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)

Role: lead

NCT05109858Completed

Skin Toxicity by Oncological Therapies

Role: lead

NCT04300101Recruiting

Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)

Role: lead

NCT06919393Recruiting

"Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL

Role: lead

NCT05208229Terminated

The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)

Role: lead

NCT06895291Recruiting

Whole Body MRI in Oncology

Role: lead

NCT04960735Not ApplicableCompleted

Implementation, Effectiveness and Impact of a Value Based Intervention for Patients with Breast or Lung Cancer

Role: collaborator

NCT03387592Phase 2Terminated

CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

Role: lead

NCT04363827Phase 2Terminated

Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)

Role: lead